Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Adam on +44 1494 818010 or adam@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Adam Woolley
Recruitment Consultant
adam@zenopa.com
+44 1494 818010

Testimonials
Sometimes you don’t realise you need a new job until someone takes the time to help you find one. Zenopa was able to assess my situation and investigate multiple opportunities that suited my career ...
James, 2013

Ferring's Firmagon shows long-term efficacy in study

1 September 2011 00:00 in Pharmaceutical Company Product News


Ferring has highlighted data from a new clinical study that supports the long-term efficacy of Firmagon, its approved treatment for prostate cancer.

Results from a study published in the Journal of Urology show that the gonadotropin-releasing hormone therapy continued to be effective and well-tolerated among patients after a three-year period.

Data was gleaned from an extension to a one-year phase III trial - which previously demonstrated Firmagon's benefits compared to leuprolide - with the three-year findings showing that its progression-free survival performance can be sustained.

Firmagon is already ratified for sale as an advanced prostate cancer therapy in both the EU and US.

Dr E David Crawford, head of urologic oncology at the University of Colorado Denver, said: "Being able to delay castration resistance for as long as possible is an important outcome for any first-line therapy."

Last month, InPharm reported that Ferring has relocated to a new UK base at Drayton Hall near London, which will help to support its continued growth in the region.ADNFCR-8000103-ID-800716060-ADNFCR

Other news stories from 01/09/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd